Gastric/esophageal/gastroesophageal junction (GEJ) adenocarcinoma

Clinical trials for Gastric/esophageal/gastroesophageal junction (GEJ) adenocarcinoma explained in plain language.

Never miss a new study

Get alerted when new Gastric/esophageal/gastroesophageal junction (GEJ) adenocarcinoma trials appear

Sign up with your email to follow new studies for Gastric/esophageal/gastroesophageal junction (GEJ) adenocarcinoma, keep track of the ones that matter, and come back to a personal dashboard instead of checking manually.

Our safety recommendation!

By submitting, you agree to our Terms of use

Trials to join now! 1

New biologic drug DBC-664 takes aim at Hard-to-Treat cancers

Disease control Recruiting now

This early-phase trial is testing an experimental biologic drug, DBC-664, in adults with advanced solid tumors such as ovarian, lung, and stomach cancers that have spread or come back. The study has two parts: first, finding a safe dose, and then expanding to see how well the dru…

Matched conditions: GASTRIC/ESOPHAGEAL/GASTROESOPHAGEAL JUNCTION (GEJ) ADENOCARCINOMA

Phase 1 • Sponsor: Duboce Biopharmaceuticals, Inc. • Aim: Disease control

Last updated Aug 23, 2026 00:00 UTC

Gastric/esophageal/gastroesophageal junction (GEJ) adenocarcinoma

Get alerted when new Gastric/esophageal/gastroesophageal junction (GEJ) adenocarcinoma trials appear

New biologic drug DBC-664 takes aim at Hard-to-Treat cancers